| Issue |
Section |
Title |
File |
| Vol 1, No 2 (2012) |
REVIEW |
Chemotherapy of metastatic colon cancer |
(Rus)
|
| Vol 3, No 2 (2014) |
REVIEW |
ADJUVANT CHEMOTHERAPY AFTER RECTAL CANCER CHEMORADIOTHERAPY |
(Rus)
|
| Vol 3, No 3 (2014) |
REVIEW |
PROMISES FOR TREATING COLON CANCER PATIENTS WITH BRAF GENE MUTATION |
(Rus)
|
| Vol 1, No 3 (2012) |
REVIEW |
Role of microsatellite instability in colon cancer |
(Rus)
|
| Vol 3, No 4 (2014) |
REVIEW |
FIRST-LINE TREATMENT IN PATIENTS WITH INOPERABLE METASTATIC COLON CANCER |
(Rus)
|
| Vol 2, No 4 (2013) |
REVIEW |
BIOLOGICAL MARKERS OF RECTAL CANCER NEOADJUVANT CHEMORADIOTHERAPY EFFICACY |
(Rus)
|
| Vol 5, No 1 (2015) |
REVIEW |
CHOICE OF TARGETED DRUG FOR SECOND-LINE METASTATIC COLON CANCER CHEMOTHERAPY |
(Rus)
|
| Vol 5, No 3 (2015) |
REVIEW |
Does asymptomatic primary tumor need to be removed in unresectable metastatic colon cancer? |
(Rus)
|
| Vol 6, No 2 (2016) |
ORIGINAL REPORTS |
Factors associated with the efficiency of maintenance therapy in patients with metastatic colorectal cancer |
(Rus)
|
| Vol 7, No 1 (2017) |
ORIGINAL REPORTS |
Meta-analysis of clinical trials on concordance of mutational stauts of primary tumour and distant metastases of colorectal cancer |
(Rus)
|
| Vol 7, No 2 (2017) |
REVIEW |
Pharmacoeconomic-guided choice of systemic chemotherapy in metastatic colorectal cancer patients |
(Rus)
|
| Vol 7, No 3 (2017) |
ORIGINAL REPORTS |
Effect of cancer drugs in patients with metastatic colorectal cancer in terms of mortality reduction |
(Rus)
|
| Vol 7, No 3 (2017) |
REVIEW |
Localization of the primary tumor of the colon: аre there essential differences? |
(Rus)
|
| Vol 8, No 1 (2018) |
REVIEW |
Some aspects of immunotherapy in colon cancer |
(Rus)
|
| Vol 8, No 1 (2018) |
ORIGINAL REPORTS |
Efficacy of first-line oxaliplatin-based chemotherapy regimens depending on the KRAS mutation status |
(Rus)
|
| Vol 8, No 2 (2018) |
ORIGINAL REPORTS |
Role of adjuvant chemotherapy in patients with rectal cancer after preoperative chemoradiotherapy: results of a retrospective study |
(Rus)
|
| Vol 8, No 2 (2018) |
ORIGINAL REPORTS |
Efficacy of continuing anti-angiogenic agents in the second-line treatment for metastatic colon cancer depending on the KRAS mutation status: a meta-analysis |
(Rus)
|
| Vol 8, No 4 (2018) |
LITERATURE REVIEW |
Colorectal cancer, screening: achievements и opportunities |
(Rus)
|
| Vol 9, No 1 (2019) |
ORIGINAL REPORT |
Optimal number of lymph nodes to be examined in stage II colon cancer |
(Rus)
|
| Vol 9, No 1 (2019) |
ORIGINAL REPORT |
Metastasectomy in patients with non-resectable metastatic colorectal cancer receiving chemotherapy and anti-EGFR antibodies: a prospective, non-randomized, multicenter, phase II study |
(Rus)
|
| Vol 9, No 2 (2019) |
ORIGINAL REPORT |
Factors associated with efficacy of FOLFIRI/aflibercept in patients with metastatic colon cancer |
(Rus)
|
| Vol 9, No 4 (2019) |
ORIGINAL REPORT |
FOLFOXIRI in patients with colon cancer and isolated non-resectable liver metastases: phase II prospective non-randomized single-center study |
(Rus)
|
| Vol 11, No 1 (2021) |
ORIGINAL REPORT |
Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study |
(Rus)
|
| Vol 11, No 3-4 (2021) |
ORIGINAL REPORT |
Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study |
(Rus)
|
| Vol 12, No 1 (2022) |
ORIGINAL REPORTS |
Concordance between the tumor mutational status and circulating tumor DNA in patients with colorectal cancer |
(Rus)
|
| Vol 12, No 2 (2022) |
LITERATURE REVIEW |
Neoadjuvant therapy for locally advanced rectal cancer |
(Rus)
|
| Vol 12, No 2 (2022) |
LITERATURE REVIEW |
Neoadjuvant chemotherapy for colon cancer |
(Rus)
|
| Vol 12, No 3 (2022) |
ORIGINAL REPORT |
Personalized therapy in solid tumors: results of a retrospective multicentre study of the clinical applicability of the FoundationOne® Medicine Test |
(Rus)
|
| Vol 12, No 3 (2022) |
LITERATURE REVIEW |
Chemotherapy for advanced pancreatic cancer in older patients (literature review) |
(Rus)
|
| Vol 13, No 2 (2023) |
ORIGINAL REPORTS |
The results of treatment for resectable gastric cancer with microsatellite instability |
(Rus)
|
| Vol 14, No 1 (2024) |
LITERATURE REVIEW |
Changes in clinical guidelines for the treatment of colorectal cancer in 2024 |
(Rus)
|
| Vol 14, No 2 (2024) |
ORIGINAL REPORT |
Efficacy and safety of different chemotherapy regimens in patients with disseminated pancreatic cancer over 65 years old |
(Rus)
|
| Vol 14, No 4 (2024) |
LITERATURE REVIEW |
Metastatic colon cancer: clinical practice guideline update in 2024 |
(Rus)
|
| Vol 14, No 4 (2024) |
ORIGINAL REPORT |
Prognostic and predictive factors in patients with metastatic gastric cancer treated with immune checkpoint inhibitors |
(Rus)
|
| Vol 15, No 1 (2025) |
ORIGINAL REPORTS |
Three-year results of the Russian multicenter prospective randomized trial RuCort3 |
(Rus)
|
| Vol 15, No 1 (2025) |
ORIGINAL REPORTS |
Characteristics of KRAS gene mutations in real clinical practice for pancreatic cancer |
(Rus)
|
| Vol 15, No 2 (2025) |
ORIGINAL REPORT |
Analysis of prognosis factors in patients with metastatic HER2‑positive gastric/cardioesophageal transition cancer treated in oncological clinics of Moscow |
(Rus)
|
| Vol 15, No 3 (2025) |
LITERATURE REVIEW |
Resolution of the round table “Possibilities for modification of colorectal cancer progression risk factors in guidelines of the professional associations” |
(Rus)
|
